JP2023530704A5 - - Google Patents
Info
- Publication number
- JP2023530704A5 JP2023530704A5 JP2022577426A JP2022577426A JP2023530704A5 JP 2023530704 A5 JP2023530704 A5 JP 2023530704A5 JP 2022577426 A JP2022577426 A JP 2022577426A JP 2022577426 A JP2022577426 A JP 2022577426A JP 2023530704 A5 JP2023530704 A5 JP 2023530704A5
- Authority
- JP
- Japan
- Prior art keywords
- derived
- car
- cells
- receptor
- ipsc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026002868A JP2026081256A (ja) | 2020-06-19 | 2026-01-09 | 免疫療法で使用するためのｉＰＳＣ由来エフェクター細胞型の組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063041672P | 2020-06-19 | 2020-06-19 | |
| US63/041,672 | 2020-06-19 | ||
| PCT/US2021/038134 WO2021258016A1 (en) | 2020-06-19 | 2021-06-18 | Combining ipsc-derived effector cell types for immunotherapy use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026002868A Division JP2026081256A (ja) | 2020-06-19 | 2026-01-09 | 免疫療法で使用するためのｉＰＳＣ由来エフェクター細胞型の組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023530704A JP2023530704A (ja) | 2023-07-19 |
| JP2023530704A5 true JP2023530704A5 (enExample) | 2024-06-25 |
Family
ID=79025356
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022577426A Pending JP2023530704A (ja) | 2020-06-19 | 2021-06-18 | 免疫療法で使用するためのｉＰＳＣ由来エフェクター細胞型の組み合わせ |
| JP2026002868A Pending JP2026081256A (ja) | 2020-06-19 | 2026-01-09 | 免疫療法で使用するためのｉＰＳＣ由来エフェクター細胞型の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026002868A Pending JP2026081256A (ja) | 2020-06-19 | 2026-01-09 | 免疫療法で使用するためのｉＰＳＣ由来エフェクター細胞型の組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12275955B2 (enExample) |
| EP (1) | EP4168538B1 (enExample) |
| JP (2) | JP2023530704A (enExample) |
| KR (1) | KR20230040337A (enExample) |
| CN (1) | CN116096386A (enExample) |
| AU (1) | AU2021292695A1 (enExample) |
| BR (1) | BR112022025806A2 (enExample) |
| CA (1) | CA3182852A1 (enExample) |
| IL (1) | IL299106B2 (enExample) |
| MX (1) | MX2022015863A (enExample) |
| WO (1) | WO2021258016A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202241935A (zh) * | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| WO2023129937A1 (en) * | 2021-12-29 | 2023-07-06 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof |
| EP4508193A4 (en) * | 2022-04-11 | 2026-04-29 | In8Bio Inc | IPSC-BASED GAMMA-DELTA T LYMPHOCYTES: COMPOSITIONS AND METHODS OF USE |
| CN116948012B (zh) * | 2022-04-13 | 2024-07-26 | 星奕昂(上海)生物科技有限公司 | 增强细胞功能的cd16抗剪切突变体 |
| US20250090582A1 (en) * | 2022-06-08 | 2025-03-20 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof |
| EP4663762A4 (en) * | 2023-03-02 | 2026-07-29 | Hongkong Bioheng Biotech Ltd | TRANSFORMED CELL RESISTANT TO IMMUNE REJECTION |
| CN117305241B (zh) * | 2023-11-28 | 2024-03-19 | 上海兴瑞一达生物科技有限公司 | 一种hiPSCs诱导分化为NK细胞的方法 |
| CN118389421A (zh) * | 2024-04-01 | 2024-07-26 | 苏州艾凯利元生物科技有限公司 | 一种体外评估nk细胞群的特性的方法 |
| WO2026073244A1 (en) * | 2024-09-30 | 2026-04-02 | Ensoma, Inc. | Constructs for multi-lineage expression of therapeutic agents |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| PT2816112T (pt) | 2009-12-10 | 2018-11-20 | Univ Iowa State Res Found Inc | Modificação do adn modificada pelo efector tal |
| WO2011159726A2 (en) | 2010-06-14 | 2011-12-22 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| MX2014001222A (es) | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| IL305629A (en) | 2013-02-15 | 2023-11-01 | Univ California | Chimeric antigen receptor and methods of using it |
| EP3789487A1 (en) * | 2013-04-03 | 2021-03-10 | Memorial Sloan Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| US9932607B2 (en) | 2013-11-15 | 2018-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Site-specific integration of transgenes into human cells |
| EP3104866A4 (en) | 2014-02-14 | 2017-08-02 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
| DK3105335T3 (da) | 2014-02-14 | 2020-01-13 | Univ Texas | Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf |
| CN120536341A (zh) | 2014-03-04 | 2025-08-26 | 菲特治疗公司 | 改良的重编程方法和细胞培养平台 |
| CN113699159A (zh) | 2014-03-28 | 2021-11-26 | 明尼苏达大学评议会 | 涉及经工程改造的cd16的多肽、细胞和方法 |
| AU2015312117A1 (en) | 2014-09-02 | 2017-03-02 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides |
| CN117737124A (zh) | 2015-10-16 | 2024-03-22 | 菲特治疗公司 | 用于诱导和维护基态多能性的平台 |
| US12642852B1 (en) * | 2015-11-04 | 2026-06-02 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
| CN122146606A (zh) | 2015-11-04 | 2026-06-05 | 菲特治疗公司 | 用于诱导造血细胞分化的方法和组合物 |
| CA3007473A1 (en) | 2015-12-14 | 2017-06-22 | Bellicum Pharmaceuticals, Inc. | Dual controls for therapeutic cell activation or elimination |
| JP7653759B2 (ja) | 2016-01-20 | 2025-03-31 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| US12247226B2 (en) | 2017-10-11 | 2025-03-11 | Fate Therapeutics, Inc. | Cellular reprogramming using temporal and transient plasmid vector expression system |
| CN111556892A (zh) * | 2017-12-08 | 2020-08-18 | 菲特治疗公司 | 使用增强的iPSC衍生的效应细胞的免疫疗法 |
| BR112020011017A2 (pt) * | 2017-12-22 | 2020-11-17 | Fate Therapeutics, Inc. | células efetoras imunes intensificadas e uso das mesmas |
| AU2019243315A1 (en) * | 2018-03-29 | 2020-09-24 | Fate Therapeutics, Inc. | Engineered immune effector cells and use thereof |
| JP2022510207A (ja) * | 2018-12-02 | 2022-01-26 | フェイト セラピューティクス，インコーポレイテッド | 増強されたｉＰＳＣ派生エフェクター細胞を使用した免疫療法 |
| CN113906133A (zh) | 2019-04-11 | 2022-01-07 | 菲特治疗公司 | 工程改造的iPSC和免疫效应细胞中的CD3重建 |
-
2021
- 2021-06-18 KR KR1020237001980A patent/KR20230040337A/ko active Pending
- 2021-06-18 MX MX2022015863A patent/MX2022015863A/es unknown
- 2021-06-18 AU AU2021292695A patent/AU2021292695A1/en active Pending
- 2021-06-18 WO PCT/US2021/038134 patent/WO2021258016A1/en not_active Ceased
- 2021-06-18 CN CN202180055596.3A patent/CN116096386A/zh active Pending
- 2021-06-18 JP JP2022577426A patent/JP2023530704A/ja active Pending
- 2021-06-18 CA CA3182852A patent/CA3182852A1/en active Pending
- 2021-06-18 EP EP21824823.5A patent/EP4168538B1/en active Active
- 2021-06-18 US US18/002,248 patent/US12275955B2/en active Active
- 2021-06-18 BR BR112022025806A patent/BR112022025806A2/pt unknown
-
2022
- 2022-12-14 IL IL299106A patent/IL299106B2/en unknown
-
2025
- 2025-03-14 US US19/080,511 patent/US20250313802A1/en active Pending
-
2026
- 2026-01-09 JP JP2026002868A patent/JP2026081256A/ja active Pending